The study aimed to compare various survival prognostic models for patients with metastatic bone disease in the long bones of a Chilean population.
This multicentric retrospective analysis involved reviewing the medical records of 136 surgically treated patients from 2016 to 2019, assessing predictive survival times using four specific scoring systems.
The findings indicated that the PathFx model was most accurate for 3 and 6-month predictions, while the IOR score was better for 12-month survival, with an overall 44% survival rate after one year.